Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$0.28.

  • Editas Medicine's EPS (Basic) rose 6266.67% to -$0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 629.92%. This contributed to the annual value of -$2.88 for FY2024, which is 4254.78% down from last year.
  • Per Editas Medicine's latest filing, its EPS (Basic) stood at -$0.28 for Q3 2025, which was up 6266.67% from -$0.63 recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's EPS (Basic) registered a high of -$0.21 during Q4 2023, and its lowest value of -$0.92 during Q1 2025.
  • In the last 5 years, Editas Medicine's EPS (Basic) had a median value of -$0.74 in 2022 and averaged -$0.67.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 53846.15% in 2021, then skyrocketed by 7613.64% in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's EPS (Basic) stood at -$0.61 in 2021, then plummeted by 44.26% to -$0.88 in 2022, then soared by 76.14% to -$0.21 in 2023, then crashed by 162.52% to -$0.55 in 2024, then soared by 49.21% to -$0.28 in 2025.
  • Its EPS (Basic) stands at -$0.28 for Q3 2025, versus -$0.63 for Q2 2025 and -$0.92 for Q1 2025.